533 related articles for article (PubMed ID: 25111682)
21. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
22. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
24. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
Kiechl S; Werner P; Knoflach M; Furtner M; Willeit J; Schett G
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):801-11. PubMed ID: 17173497
[TBL] [Abstract][Full Text] [Related]
25. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
26. [The participation of RANK, RANKL and OPG in tumor osteolysis].
Stanisławowski M; Kmieć Z
Postepy Hig Med Dosw (Online); 2009 May; 63():234-41. PubMed ID: 19502684
[TBL] [Abstract][Full Text] [Related]
27. [Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor].
Kushlinskiĭ NE; Timofeev IuS; Gershteĭn ES; Solov'ev IuN
Vopr Onkol; 2014; 60(4):413-21. PubMed ID: 25552059
[TBL] [Abstract][Full Text] [Related]
28. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
29. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J; Wang K; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
31. Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
Pivonka P; Zimak J; Smith DW; Gardiner BS; Dunstan CR; Sims NA; Martin TJ; Mundy GR
J Theor Biol; 2010 Jan; 262(2):306-16. PubMed ID: 19782692
[TBL] [Abstract][Full Text] [Related]
32. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology.
Melchiorre D; Milia AF; Linari S; Romano E; Benelli G; Manetti M; Guiducci S; Ceccarelli C; Innocenti M; Carulli C; Civinini R; Morfini M; Matucci-Cerinic M; Ibba-Manneschi L
J Rheumatol; 2012 Aug; 39(8):1678-86. PubMed ID: 22753650
[TBL] [Abstract][Full Text] [Related]
33. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
34. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
35. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
36. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
37. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves.
Steinmetz M; Skowasch D; Wernert N; Welsch U; Preusse CJ; Welz A; Nickenig G; Bauriedel G
J Heart Valve Dis; 2008 Mar; 17(2):187-93. PubMed ID: 18512489
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Marley K; Bracha S; Seguin B
Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
[TBL] [Abstract][Full Text] [Related]
39. RANK/RANKL/OPG system in the intervertebral disc.
Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
[TBL] [Abstract][Full Text] [Related]
40. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis.
Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX
COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
